Ardelyx (ARDX), Raymond James up Price Target, Citigroup Joins the Party.
Wall Street Cozy's up to Ardelyx After New Guidance.
On January 8th, Mike Raab, President and Chief Executive...
Bridging the Immunity Gap: An In-Depth Conversation with GeoVax’s (GOVX) CEO, David Dodd
In an era of rapid scientific development, the pharmaceutical industry constantly evolves to meet new challenges and seize emerging opportunities. GeoVax, a...
GeoVax to Present at World Vaccine Congress, Thursday April 4th.
Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation non-MRNA Covid-19 vaccine...
China Remains at Risk to Future MonkeyPox Outbreaks.
GeoVax (GOVX) intends to become the first U.S.-based supplier of the MVA vaccine to prevent Mpox and smallpox.
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial!
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants
We were having cocktails at...
Geovax (GOVX) – City of Hope Covid Vaccine for Chronic Lymphocytic Leukemia Patients. Interview...
Explosive Interview About GeoVax's Covid vaccine with the brilliant Dr. Don J. Diamond, Ph.D., professor at City of Hope and GeoVax...
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
Cybin (CYBN) Announces Unprecedented Positive Phase 2 Data After Single Dose.
Conference call to discuss CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET
Interviews With Dr. Don Diamond, Lead Developer in the GeoVax (GOVX) Vaccine for Leukemia...
Dr. Don Diamond has stated, "The City of Hope is excited to license this vaccine to GeoVax (GOVX) to progress to large-scale...
IMAC Holdings (BACK) Explodes 94% Higher Post Reverse Split, With 42 Million Shares Trading...
Simply Incredible! 2024 Will be the Year of Post Reverse Split Revenge!
Taking advantage of post reverse-split investor...